Literature DB >> 6207763

Evaluation of beta-D-galactosidase from Escherichia coli and horseradish peroxidase as labels by sandwich enzyme immunoassay technique.

M Imagawa, S Hashida, Y Ohta, E Ishikawa.   

Abstract

beta-D-galactosidase from Escherichia coli and horseradish peroxidase were evaluated as labels of Fab' in dose-response curves for human alpha-fetoprotein and human chorionic gonadotropin by sandwich enzyme immunoassay technique using fluorogenic substrates for enzyme assay. The non-specific binding of Fab'-peroxidase conjugates to IgG-coated polystyrene balls was less than that of Fab'-beta-D-galactosidase conjugates, and the affinity-purified Fab'-peroxidase conjugates gave more sensitive dose-response curves for these antigens than the corresponding beta-D-galactosidase conjugates. However, a large quantity of Fab'-peroxidase conjugates was required and a longer incubation was necessary for the peroxidase assay, since the peroxidase assay was much less sensitive than the beta-D-galactosidase assay. Other advantages and disadvantages of the two enzymes are discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6207763     DOI: 10.1177/000456328402100414

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  9 in total

1.  Use of indirectly immobilized recombinant p17 antigen for detection of antibodies to HIV-1 by enzyme immunoassay.

Authors:  S Ishikawa; K Hashinaka; S Hashida; S Oka; E Ishikawa
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

2.  Immune complex transfer enzyme immunoassay for antibody IgM to HIV-1 p17 antigen.

Authors:  S Hashida; S Ishikawa; I Nishikata; K Hashinaka; S Oka; E Ishikawa
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

3.  Sensitive enzyme immunoassay of antibodies to HIV-1 p17 antigen using indirectly immobilized recombinant p17 for diagnosis of HIV-1 infection.

Authors:  S Ishikawa; K Hashinaka; S Hashida; S Oka; E Ishikawa
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

4.  Optimal conditions of immune complex transfer enzyme immunoassays for antibody IgGs to HIV-1 using recombinant p17, p24, and reverse transcriptase as antigens.

Authors:  S Hashida; S Ishikawa; K Hashinaka; I Nishikata; S Oka; K Shimada; A Saito; A Takamizawa; H Shinagawa; E Ishikawa
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

5.  More sensitive immune complex transfer enzyme immunoassay for antibody IgG to p17 of HIV-1 with shorter incubation time for immunoreactions and larger volumes of serum samples.

Authors:  S Ishikawa; S Hashida; K Hashinaka; M Kojima; A Saito; A Takamizawa; H Shinagawa; S Oka; K Shimada; E Ishikawa
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

6.  Recombinant p51 as antigen in an immune complex transfer enzyme immunoassay of immunoglobulin G antibody to human immunodeficiency virus type 1.

Authors:  K Hashinaka; S Hashida; I Nishikata; A Adachi; S Oka; E Ishikawa
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

7.  Earlier detection of human immunodeficiency virus type 1 p24 antigen and immunoglobulin G and M antibodies to p17 antigen in seroconversion serum panels by immune complex transfer enzyme immunoassays.

Authors:  S Hashida; S Ishikawa; K Hashinaka; I Nishikata; S Oka; E Ishikawa
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

8.  Optimal conditions of immune complex transfer enzyme immunoassay for p24 antigen of HIV-1.

Authors:  S Hashida; S Ishikawa; K Hashinaka; I Nishikata; A Saito; A Takamizawa; H Shinagawa; E Ishikawa
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

9.  Measurement of human immunodeficiency virus type 1 p24 in serum by an ultrasensitive enzyme immunoassay, the two-site immune complex transfer enzyme immunoassay.

Authors:  S Hashida; K Hashinaka; I Nishikata; S Oka; K Shimada; A Saitoh; A Takamizawa; H Shinagawa; E Ishikawa
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.